Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Event-Driven

<p>Sinovac's vaccine for EV71 (Hand Foot and Mouth disease) launched in China's private market this summer after disruptions caused by the infamous fake vaccine scandal centered in Shandong province.  While data regarding the pace of the vaccinations hasn't surfaced, public information regarding pricing suggests levels consistent with our previous analyses that support our opinion that the EV71 vaccine alone is worth US$9 dollars/share. </p><p>We continue to think that the outstanding offers for the company (highest at US$7/share) undervalue the business.</p>

Sinovac's vaccine for EV71 (Hand Foot and Mouth disease) launched in China's private market this summer after disruptions caused by the infamous fake vaccine scandal centered in Shandong province.  While data regarding the pace of the vaccinations hasn't surfaced, public information regarding pricing suggests levels consistent with our previous analyses that support our opinion that the EV71 vaccine alone is worth US$9 dollars/share. We continue to think that the outstanding offers for the company (highest at US$7/share) undervalue the business.

Sinovac Biotech

EV71 Prices in Line: Now About That Bid